Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Therapeutics and Clinical Risk Management. 2008 Jun;4(3):579-85. [Link] Felip E, Rosell R. Vall d’Hebron University Hospital Barcelona, Spain. Abstract NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with…

Read More

Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial

Prescrire International. 2005 Dec;14(80):212-4. [Link] Abstract (1) Chemotherapy does not appear to prolong the survival of patients with inoperable pleural mesothelioma, and the tumour response rate barely exceeds 20%. A combination of cisplatin + doxorubicin seems to provide the best response rates. (2) In a trial of second-line docetaxel therapy in patients with non small…

Read More